PAR 5.36% 29.5¢ paradigm biopharmaceuticals limited..

Ann: PARADIGM TREATS FIRST SUBJECTS IN PHASE 3 TRIAL OF ZILOSUL, page-6

  1. 360 Posts.
    lightbulb Created with Sketch. 42
    Very pleased to finally have the first patients recruited and injected
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.